Authors
Yiyan Yang, Tomoko Takai, Naoya Hatano, Yoji Murata, Takashi Matozaki, Yoshimasa Maniwa, Takenori Kotani
Published in
The Kobe journal of medical sciences. Volume 72. Issue 2. Pages E77-E88. Aug 31, 2026. Epub Aug 31, 2026.
Abstract
The transmembrane protein CD47 expressed on tumor cells suppresses Fcγ receptor-mediated antibody-dependent cellular phagocytosis (ADCP) through its interaction with signal regulatory protein α (SIRPα), a transmembrane protein expressed on phagocytic cells such as macrophages. Although blockade of the CD47-SIRPα interaction enhances the efficacy of tumor-targeting antibodies such as rituximab, its antitumor activity remains limited in cancers lacking defined tumor-associated antigens. In this study, we identified the membrane protein Basigin and SIRPα as broadly applicable therapeutic targets for cancer. We found that the 8H4 antibody, originally identified in the course of other research, recognized mouse Basigin, suppressed proliferation of diverse cancer cell types, and induced cancer cell death. Treatment with the 8H4 antibody indeed inhibited tumor growth in vivo. Moreover, combined treatment with the 8H4 antibody and an anti-SIRPα antibody that blocks the CD47-SIRPα interaction markedly enhanced macrophage-mediated ADCP against diverse cancer cell types in vitro. These results suggest that targeting Basigin, particularly in combination with SIRPα blockade, may provide a basis for the development of macrophage-mediated immunotherapies applicable to cancers in which tumor-associated antigens have not yet been identified.
PMID:
42805911
Bibliographic data and abstract were imported from PubMed on 29 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 18
- Comments 0